160 related articles for article (PubMed ID: 37558486)
1. Late-onset Myoclonic Seizure in a 78-year-old Woman with Gaucher Disease.
Yamaguchi-Takegami N; Takahashi A; Mitsui J; Sugiyama Y; Chikada A; Porto KJL; Takegami N; Sakuishi K; Ishiura H; Yamada K; Shimizu J; Tsuji S; Toda T
Intern Med; 2024 Mar; 63(6):861-865. PubMed ID: 37558486
[TBL] [Abstract][Full Text] [Related]
2. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.
Sawicka-Gutaj N; Machaczka M; Kulińska-Niedziela I; Bernardczyk-Meller J; Gutaj P; Sowiński J; Ruchała M
Ups J Med Sci; 2016 Aug; 121(3):192-5. PubMed ID: 27064303
[TBL] [Abstract][Full Text] [Related]
3. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
4. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
5. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
[TBL] [Abstract][Full Text] [Related]
6. Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.
Kim EA; Lim YT; Hah JO; Sohn YB; Kim YK; Choi JH; Kim SY; Jang KM; Ahn J; Lee JM
Int J Hematol; 2019 Mar; 109(3):361-365. PubMed ID: 30456712
[TBL] [Abstract][Full Text] [Related]
7. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
Donald A; Björkvall CK; Vellodi A; ; Cox TM; Hughes D; Jones SA; Wynn R; Machaczka M
Orphanet J Rare Dis; 2022 Jun; 17(1):234. PubMed ID: 35717194
[TBL] [Abstract][Full Text] [Related]
8. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
[TBL] [Abstract][Full Text] [Related]
9. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
[TBL] [Abstract][Full Text] [Related]
10. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
11. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
Elstein D; Abrahamov A; Altarescu G; Zimran A
Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
[No Abstract] [Full Text] [Related]
12. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients.
Tantawy AAG; Adly AAM; Abdeen MSED; Salah NY
Neurogenetics; 2020 Jul; 21(3):159-167. PubMed ID: 32215803
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation causing type 1 Gaucher disease found in a Japanese patient with gastric cancer: A case report.
Hosoba S; Kito K; Teramoto Y; Adachi K; Nakanishi R; Asai A; Iwasa M; Nishimura R; Moritani S; Kawahara M; Minamiguchi H; Nanba E; Kushima R; Andoh A
Medicine (Baltimore); 2018 Jul; 97(27):e11361. PubMed ID: 29979419
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary hemorrhage in type 3 Gaucher disease: a case report.
Vellodi A; Ashworth M; Finnegan N; Wallis C
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S329-31. PubMed ID: 20689991
[TBL] [Abstract][Full Text] [Related]
16. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.
Tantawy AA; Sherif EM; Adly AA; Hassanine S; Awad AH
J Inherit Metab Dis; 2013 Nov; 36(6):1025-37. PubMed ID: 23508695
[TBL] [Abstract][Full Text] [Related]
17. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
18. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.
Daykin EC; Ryan E; Sidransky E
Mol Genet Metab; 2021 Feb; 132(2):49-58. PubMed ID: 33483255
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
